Pawlotsky J-M
Inserm U955, Centre National de Reférence des Hépatites Virales B, C et Delta, Laboratoire de Virologie, Université Paris-12, Hôpital Henri-Mondor, 94010 Créteil cedex, France.
Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):903-7. doi: 10.1016/j.gcb.2009.07.018. Epub 2009 Aug 31.
The past 30 years have been witnessing major progress in the knowledge and management of liver diseases. Approximately 29 million people in European Union suffer from chronic liver disease. However, liver diseases have been neglected by most European and national political and public health deciders. A number of measures should be implemented at the European and country levels: an efficient surveillance and data collection policy; broad information of the general population on the nature and importance of liver diseases and the means to diagnose and treat them; treatment and management policies; promotion of research on the causes, risk factors, prevention and management of liver diseases as well as on the most efficient interventions to reduce their incidence, prevalence, morbidity and mortality. The European Association for the Study of the Liver (EASL) has launched in 2006 an ambitious public policy and communication action in order to get recognition of liver diseases as a major cause of morbidity and mortality in Europe and push for appropriate measures. The future of hepatology as a specialty will depend on the success of this initiative.
在过去30年里，肝病的知识和管理取得了重大进展。欧盟约有2900万人患有慢性肝病。然而，大多数欧洲和国家的政治及公共卫生决策者一直忽视肝病问题。应在欧洲和国家层面实施一系列措施：高效的监测和数据收集政策；向普通民众广泛宣传肝病的性质、重要性以及诊断和治疗方法；治疗和管理政策；推动对肝病的病因、风险因素、预防和管理以及降低其发病率、患病率、发病率和死亡率的最有效干预措施的研究。欧洲肝脏研究协会（EASL）于2006年发起了一项雄心勃勃的公共政策和宣传行动，以使肝病被认可为欧洲发病和死亡的主要原因，并推动采取适当措施。肝病学作为一门专业的未来将取决于这项倡议的成功。
